741 related articles for article (PubMed ID: 23636449)
1. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study.
Lavau-Denes S; Lacroix P; Maubon A; Preux PM; Genet D; Vénat-Bouvet L; Labourey JL; Martin J; Slaouti P; Tubiana-Mathieu N
Cancer Chemother Pharmacol; 2013 Jul; 72(1):65-73. PubMed ID: 23636449
[TBL] [Abstract][Full Text] [Related]
2. Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia.
Del Principe MI; Buccisano F; Maurillo L; Venditti D; Cefalo M; Sarlo C; Di Caprio L; Di Veroli A; Nasso D; Ceresoli E; Postorino M; Di Piazza F; Colandrea G; Conti F; Del Poeta G; Amadori S; Venditti A
Thromb Res; 2013 Nov; 132(5):511-4. PubMed ID: 24090605
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
Mismetti P; Mille D; Laporte S; Charlet V; Buchmüller-Cordier A; Jacquin JP; Fournel P; Dutrey-Dupagne C; Decousus H;
Haematologica; 2003 Jan; 88(1):67-73. PubMed ID: 12551829
[TBL] [Abstract][Full Text] [Related]
4. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
[TBL] [Abstract][Full Text] [Related]
5. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
6. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
Hull R; Raskob G; Pineo G; Rosenbloom D; Evans W; Mallory T; Anquist K; Smith F; Hughes G; Green D
N Engl J Med; 1993 Nov; 329(19):1370-6. PubMed ID: 8413432
[TBL] [Abstract][Full Text] [Related]
7. Expedited discharge in trauma patients requiring anticoagulation for deep venous thrombosis prophylaxis: the LEAP Program.
Bridges GG; Lee MD; Jenkins JK; Stephens MA; Croce MA; Fabian TC
J Trauma; 2003 Feb; 54(2):232-5. PubMed ID: 12579045
[TBL] [Abstract][Full Text] [Related]
8. Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients.
Farge D; Durant C; Villiers S; Long A; Mahr A; Marty M; Debourdeau P;
Thromb Res; 2010 Apr; 125 Suppl 2():S108-16. PubMed ID: 20433988
[TBL] [Abstract][Full Text] [Related]
9. Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients.
Delluc A; Le Gal G; Scarvelis D; Carrier M
Thromb Res; 2015 Feb; 135(2):298-302. PubMed ID: 25491940
[TBL] [Abstract][Full Text] [Related]
10. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
11. [Venous thromboembolism associated with long-term use of central venous catheters in cancer patients].
Debourdeau P; Chahmi DK; Zammit C; Farge-Bancel D
Pathol Biol (Paris); 2008 Jun; 56(4):211-9. PubMed ID: 18395994
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy after catheter-directed thrombolysis for acute iliofemoral deep venous thrombosis.
Jørgensen M; Broholm R; Bækgaard N
Phlebology; 2013 Mar; 28 Suppl 1():34-8. PubMed ID: 23482532
[TBL] [Abstract][Full Text] [Related]
13. Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin.
Saccullo G; Malato A; Raso S; Santoro M; Zammit V; Casuccio A; Siragusa S
Am J Hematol; 2012 Apr; 87(4):388-91. PubMed ID: 22374861
[TBL] [Abstract][Full Text] [Related]
14. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients.
Verso M; Agnelli G
J Clin Oncol; 2003 Oct; 21(19):3665-75. PubMed ID: 14512399
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
17. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparin for deep vein thrombosis in glioma patients.
Schmidt F; Faul C; Dichgans J; Weller M
J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
[TBL] [Abstract][Full Text] [Related]
19. Early follow-up and treatment recommendations for isolated calf deep venous thrombosis.
Singh K; Yakoub D; Giangola P; DeCicca M; Patel CA; Marzouk F; Giangola G
J Vasc Surg; 2012 Jan; 55(1):136-40. PubMed ID: 21982332
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis and treatment of deep vein thrombosis in general surgery.
Gutt CN; Oniu T; Wolkener F; Mehrabi A; Mistry S; Büchler MW
Am J Surg; 2005 Jan; 189(1):14-22. PubMed ID: 15701484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
